Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869764 · ClinicalTrials.gov registry record · Phase 2
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
A Phase 2 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT01869764 is a Phase 2 study of Stage II Breast Cancer and Stage IIIA Breast Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 57 participants, below the 317-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01869764, a Phase 2 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty acid on tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG omega-3 fatty acid
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-11 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01869764
The ClinicalTrials.gov registry entry for NCT01869764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 317-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01869764 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01869764 about?
NCT01869764 is a clinical study titled "Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer". This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty a...
What is the current status of trial NCT01869764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2013-11. Estimated completion is 2018-07.
What conditions does trial NCT01869764 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Male Breast Cancer.
What interventions are being tested in trial NCT01869764?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), omega-3 fatty acid (DRUG).
Who is sponsoring clinical trial NCT01869764?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01869764 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
MARGetuximab Or Trastuzumab (MARGOT)
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
ACTIVE NOT RECRUITING · Phase 2
-
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
ACTIVE NOT RECRUITING · Phase 2
-
Acupuncture Pilot Study for Cancer-related Cognitive Function
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.